MHQ: Clinical IntelligencePowered by SurvivorNet

Medical History
Clinical Trials

?

Prefer to talk instead of typing?

Answers offered are informational and do not constitute medical advice. Learn more

Medical History

Review your patient’s information.

What is your gender?

What is your age?

Clinical Trials

Clear List

Sign In

Dr. Kaique Filardi

Dr. Kaique Filardi is a board-certified general surgeon and gastrointestinal (GI) surgeon from the University of São Paulo. He is currently an oncologic surgery research fellow at Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, and serves as a teaching assistant in the Principles and Practice of Clinical Research (PPCR) program at Harvard Medical School.

VOLGA Trial Points To Cisplatin-Free Perioperative Path in Muscle-Invasive Bladder Cancer

VOLGA Trial Points To Cisplatin-Free Perioperative Path in Muscle-Invasive Bladder Cancer

By Dr. Kaique Filardi

VIKTORIA-1 May Sharpen Post-CDK4/6 Choices in PIK3CA-Mutant HR+ Breast Cancer

VIKTORIA-1 May Sharpen Post-CDK4/6 Choices in PIK3CA-Mutant HR+ Breast Cancer

By Dr. Kaique Filardi

persevERA Breast Cancer Study Keeps Oral ER-Targeting Strategy in Focus Despite Negative Primary Result

persevERA Breast Cancer Study Keeps Oral ER-Targeting Strategy in Focus Despite Negative Primary Result

By Dr. Kaique Filardi

Mo-Rez: A New Targeted Therapy Shows Early Promise in Ovarian and Endometrial Cancers

Mo-Rez: A New Targeted Therapy Shows Early Promise in Ovarian and Endometrial Cancers

By Dr. Kaique Filardi

Cardio-Oncology Moves Towards Pathway Science: What Oncologists Should Know About Immune Signaling And The Heart

Cardio-Oncology Moves Towards Pathway Science: What Oncologists Should Know About Immune Signaling And The Heart

By Dr. Kaique Filardi

Combining Targeted Therapy & Chemo: How BREAKWATER Has Changed The Metastatic Colorectal Cancer Landscape

Combining Targeted Therapy & Chemo: How BREAKWATER Has Changed The Metastatic Colorectal Cancer Landscape

By Dr. Kaique Filardi

From ‘Undruggable’ To Actionable: RAS Inhibitors & A Potential New Era Of Targeted Therapy For Pancreatic Cancer

From ‘Undruggable’ To Actionable: RAS Inhibitors & A Potential New Era Of Targeted Therapy For Pancreatic Cancer

By Dr. Kaique Filardi

Roswell Park’s Dr. Ehsan Malek On Sequencing Tec‑Dara & CAR T-Cell Therapy in RRMM

Roswell Park’s Dr. Ehsan Malek On Sequencing Tec‑Dara & CAR T-Cell Therapy in RRMM

By Dr. Kaique Filardi

LITESPARK-011: Belzutifan Plus Lenvatinib As A Second-Line Option For Advanced Clear-Cell Renal Cell Carcinoma

LITESPARK-011: Belzutifan Plus Lenvatinib As A Second-Line Option For Advanced Clear-Cell Renal Cell Carcinoma

By Dr. Kaique Filardi

Next-Generation FRα-Directed Agents in Ovarian Cancer: What Sofetabart Mipitecan (LY4170156) Developments Mean For Practice

Next-Generation FRα-Directed Agents in Ovarian Cancer: What Sofetabart Mipitecan (LY4170156) Developments Mean For Practice

By Dr. Kaique Filardi

The evERA Trial: A Promising Update For Patients With Metastatic ER+, HER2- Breast Cancer

The evERA Trial: A Promising Update For Patients With Metastatic ER+, HER2- Breast Cancer

By Dr. Kaique Filardi

Giredestrant + Everolimus After CDK4/6 Inhibitors: Clinical Significance of the evERA Phase 3 Trial

Giredestrant + Everolimus After CDK4/6 Inhibitors: Clinical Significance of the evERA Phase 3 Trial

By Dr. Kaique Filardi

LIDERA: The First Oral SERD to Demonstrate a Disease-Free Survival Benefit in Early-Stage HR+ Breast Cancer

LIDERA: The First Oral SERD to Demonstrate a Disease-Free Survival Benefit in Early-Stage HR+ Breast Cancer

By Dr. Kaique Filardi

Why Epkinly Is Suddenly Front and Center in Lymphoma Care — What It Means for Patients?

Why Epkinly Is Suddenly Front and Center in Lymphoma Care — What It Means for Patients?

By Dr. Kaique Filardi